Trials / Recruiting
RecruitingNCT06859710
THC and CBD: A Controlled Human Study Probing a Harm Reduction Strategy
Interactions Between Delta-9-THC and CBD: A Controlled Human Drug-administration Study Probing a Harm Reduction Strategy
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- University of California, Los Angeles · Academic / Other
- Sex
- All
- Age
- 21 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this research is to assess the impact of CBD on the effects of THC.
Detailed description
Some evidence indicates that cannabidiol (CBD), a non-intoxicating cannabis component, might mitigate certain effects of THC. This study will examine possible roles for CBD in modulating THC's adverse and analgesic effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Vaporized Placebo |
| DRUG | THC | Vaporized THC (20 mg) |
| DRUG | CBD 20 mg | Vaporized CBD (20 mg) |
| DRUG | CBD 40 mg | Vaporized CBD (40 mg) |
| DRUG | CBD 80 mg | Vaporized CBD (80 mg) |
Timeline
- Start date
- 2025-11-05
- Primary completion
- 2027-09-01
- Completion
- 2028-09-01
- First posted
- 2025-03-05
- Last updated
- 2025-12-17
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06859710. Inclusion in this directory is not an endorsement.